Ovid Therapeutics Inc. (OVID) Spending and interest coverage
- R&D / revenue · 12 months: Value 2122.30%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 302.02%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 2122.30% | Research and development expense / revenue. Period ending 2026-06-30. $33.60M ÷ $1.58M × 100 ≈ 2122.30% |
| Stock-based compensation / revenue · 12 months | 302.02% | Share-based compensation / revenue. Period ending 2026-06-30. $4.78M ÷ $1.58M × 100 ≈ 302.02% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 33.60M USD | Research and Development Expense |
| Revenue | 1.58M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 4.78M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -58.36M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $33.60M | $1.58M | $4.78M | $-58.36M | (m) | 2122.30% | 302.02% | (m) | (m) |
| 2026-03-31 | $30.10M | $7.12M | $4.57M | $-47.73M | (m) | 422.69% | 64.15% | (m) | (m) |
| 2025-12-31 | $25.58M | $7.25M | $4.81M | $-42.44M | (m) | 352.76% | 66.29% | (m) | (m) |
| 2025-09-30 | $24.92M | $6.61M | $4.87M | $-40.87M | (m) | 376.94% | 73.71% | (m) | (m) |
| 2025-06-30 | $26.91M | $6.65M | $5.07M | $-41.57M | (m) | 404.54% | 76.24% | (m) | (m) |
| 2025-03-31 | $33.03M | $548.00K | $5.59M | $-57.02M | (m) | 6027.19% | 1020.44% | (m) | (m) |
| 2024-12-31 | $36.77M | $566.00K | $6.28M | $-61.88M | (m) | 6495.94% | 1108.83% | (m) | (m) |
| 2024-09-30 | $41.49M | $631.70K | $6.81M | $-69.35M | (m) | 6567.39% | 1077.29% | (m) | (m) |
| 2024-06-30 | $38.96M | $567.70K | $7.13M | $-68.15M | (m) | 6862.64% | 1255.64% | (m) | (m) |
| 2024-03-31 | $32.37M | $473.69K | $7.34M | $-61.81M | (m) | 6833.49% | 1548.72% | (m) | (m) |
| 2023-12-31 | $28.59M | $391.69K | $7.29M | $-59.28M | (m) | 7298.51% | 1859.91% | (m) | (m) |
| 2023-09-30 | $23.50M | $296.41K | $7.23M | $-53.27M | (m) | 7928.87% | 2437.76% | (m) | (m) |
| 2023-06-30 | $23.35M | $198.54K | $7.38M | $-54.04M | (m) | 11762.22% | 3715.50% | (m) | (m) |
| 2023-03-31 | $23.40M | $123.54K | $7.15M | $-54.17M | (m) | 18941.61% | 5786.20% | (m) | (m) |
| 2022-12-31 | $24.62M | $1.50M | $6.56M | $-55.55M | (m) | 1638.23% | 436.31% | (m) | (m) |
| 2022-09-30 | $37.15M | (m) | $6.14M | $-69.73M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $36.89M | (m) | $5.52M | $-68.61M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $38.52M | (m) | $5.06M | $-68.62M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $46.94M | (m) | $5.05M | $124.21M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $45.73M | (m) | $5.79M | $128.97M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $56.69M | (m) | $7.24M | $124.25M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $65.04M | (m) | $7.54M | $115.42M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $63.42M | (m) | $7.53M | $-81.43M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $58.64M | (m) | $6.60M | $-77.11M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $54.36M | (m) | $5.17M | $-77.47M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $47.45M | (m) | $4.87M | $-67.65M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $42.16M | (m) | $5.21M | $-61.41M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $38.67M | (m) | $5.81M | $-57.27M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $35.65M | (m) | $6.32M | $-53.67M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $34.65M | (m) | $6.91M | $-53.56M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $33.79M | (m) | $7.06M | $-52.93M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $31.88M | (m) | $6.74M | $-50.85M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $29.20M | (m) | $6.43M | $-47.10M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $27.16M | (m) | $6.77M | $-44.18M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $49.97M | (m) | $6.40M | $-65.01M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $9.59M | (m) | $3.64M | $-22.54M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $6.61M | (m) | $1.46M | $-13.19M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |